21‑Valent Pneumococcal Conjugate Vaccine V116 (CAPVAXIVE®): Pediatric First Approval
{{output}}
The 21‑valent pneumococcal conjugate vaccine (PCV) V116 (CAPVAXIVE®), developed by Merck & Co., has been approved in the USA since June 2024 for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae in ad... ...
